Interferon gamma-1b

Drug Profile

Interferon gamma-1b

Alternative Names: Actimmune; IFNγ-1b; Imukin; Interferon-gamma-1b

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genentech
  • Developer Fox Chase Cancer Center; Friedreichs Ataxia Research Alliance; Horizon Pharma; InterMune
  • Class Antineoplastics; Antivirals; Interferons; Lymphokines
  • Mechanism of Action Interferon gamma stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic granulomatous disease; Pulmonary fibrosis; Friedreich's ataxia; Renal cell carcinoma; Osteopetrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Friedreich's ataxia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic granulomatous disease; Osteopetrosis
  • Phase I Solid tumours
  • No development reported Hepatitis B; Hepatitis C
  • Discontinued Atopic dermatitis; Cryptococcosis; Friedreich's ataxia; Hepatic fibrosis; Keloids; Mycoses; Non-Hodgkin's lymphoma; Ovarian cancer; Pulmonary fibrosis; Renal cell carcinoma; Systemic scleroderma; Tuberculosis

Most Recent Events

  • 27 Feb 2017 Horizon Pharma plans investigator-initiated clinical trials in 2017
  • 08 Dec 2016 Discontinued - Phase-III for Friedreich's ataxia (In adolescents, In children, In adults) in USA as the trial failed to meet its primary endpoints (SC)
  • 16 Jun 2016 Horizon Pharma plans a long-term safety extension phase III trial for Friedreich's Ataxia (In children, In adolescents, In adults) in USA (SC) (NCT02797080)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top